Dr. Olson’s research centers around improving the efficacy and safety of immunotherapy. This includes a research focus on investigator-sponsored trials targeting mechanisms of resistance to PD-1 antibody therapy. He also has a research interest in improving the management of immune-related adverse events (irAE) through translational work characterizing irAE mechanisms. Dr. Olson will work both in the melanoma and developmental therapeutics (DT) programs. Within the DT program, he will focus on trials targeting mechanisms of immunotherapy resistance, and to help expand the use of cell therapy approaches in solid tumors.